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94 Poster Session Ifrom umbilical cord blood (CB) is unknown.We performed in vitro
and in vivo studies comparing bone marrow (BM)-derived CD1331
cells from chronic coronary artery patients enrolled in the Safety
And Efficacy Of Autologous Intracoronary Stem Cell Injections
In Total Coronary Artery Occlusions (SEACOAST). Patient- and
control-derived blood cells mononuclear cells (MNC) from periph-
eral blood (PB) and BM were tested for endothelial cell colony for-
mation (CFU-EC), and tested functionally by in vitromigration and
the ability to augment blood flow in a mouse hindlimb ischemia
model. Patient-derived BM CD1331 cells, isolated with the Clini-
MACS device (84 6 7% purity and 76 6 7% viability (7–7AAD),
contained non-CD1331 cells following selection: \ 5% CD3,
CD3neg/CD56, CD19 (immature/mature), CD14, or CD71 cells,
5% CD611 cells, and 8% CD131 SSChigh cells. BM and PB-de-
rived MNC from patients produced less colonies compared to
healthy controls and CB: CB, 35.8 6 41.7, control PB, 79.6 6 49;
control BM, 24.8 6 13.7; patient PB, 6.9 6 9.3 and BM, 0.86 6
0.83. Transmigration of selected CD1331 cells to the stromal
cell-derived factor-1 (SDF-1) chemokine was performed. Transmi-
gration of control and patient-derived CD1331 cells in response to
200 ng/ml SDF-1 was 64.5 6 23.1% and 9.3 6 3.8%. Control or
patient-derived cells or media was injected (intracardiac) into
NOD/SCID mice after femoral artery ligation. Doppler flow mea-
surements comparing ischemic/healthy limb perfusion ratios at 28
days were higher in mice receiving control CD1331 cells (0.51 6
0.06) compared to those receiving media control (0.37 6 0.03, p
\ 0.05). No improvement of receiving patient-derived BM
CD1331 cells (0.46 6 0.04) or PB MNC (0.37 6 0.08) was ob-
served (p5 0.07, p5 0.94, respectively). Diminished biological po-
tency of chronic ischemic patient-derived cells was observed in in
vitro and in vivo studies when compared to cord blood and healthy
control-derived cells.254
AMD3100 MOBILIZES A MORE PRIMITIVE HEMATOPOIETIC PROGENI-
TOR SUBSET FROM HUMAN MARROW
Wagner, W.1,2, Fru¨hauf, S.1, Callandra, G.3, Ho, A.D.1. 1 University of
Heidelberg, Heidelberg, Germany; 2 University of Heidelberg, Germany;
3 Genzyme, Boston, Germany.
Our group demonstrated the significance of specific adhesion
molecules and of junction formation between human hematopoietic
progenitor cells (HPC) and human mesenchymal stromal cells
(MSC) in maintaining stemness. For example, CXCR4/SDF-1a as
well as b1-integrins were shown to be major mediators of stem
cell homing and adhesion to the niche. AMD3100, a novel
CXCR4 antagonist, inhibits efficiently the binding of CXCR4 to
SDF1a and has been shown to induce a rapid release of HPC
from the bone marrow to peripheral blood.
We have monitored migration and cell-cell adhesion of HPC to-
wards MSC under the influence of SDF-1a, AMD3100 and the ap-
propriate controls. Simultaneously we participated in amulti-center
trial sponsored by Anormed (Vancouver, Canada, subsequently
Genzyme, Boston) in patients who were poor mobilizers. Patients
with multiple myeloma and non-Hodgkin-lymphoma were treated
with AMD3100 administered 12 hours before apheresis and follow-
ing 4 days of granulocyte colony-stimulating factor (G-CSF),. This
offered the opportunity to measure the numbers, the phenotypes
and function of the CD341 cells mobilized by AMD3100 1 G-
CSF versus those by G-CSF alone in the same subjects.
The primitive subsets (CD341/CD38-) were significantly more
adherent to MSC than the committed HPC (CD341/CD381).
Functionally LTC-IC were found exclusively among the HPC ad-
herent to MSC. There was a significant reduction in adhesion of
HPC to MSC upon in vitro treatment with AMD3100 (32% 6
11%; P5 7 10–5) or with SDF-1a (55%6 13%; P5 .014), versus
controls (74%6 10%). Analysis ofHPCmobilized by AMD31001
G-CSF in the patients (n 5 7) indicated that HPC are completely
different from those mobilized with G-CSF. The most significant
findings were (1) an overall increase in the concentration of
CD341 cells after administration of AMD3100 (2.8 fold with
a range from 1.1X to 6.9X), and (2) an increase in the primitive sub-
set CD341/CD38- cells versus stimulation with G-CSF alone. Themedian increase in CD341/CD38- was 3.6 fold with a range of
1.3X to 5.7X. Parallel to this increase, functional assay also indi-
cated that the CD341 cells mobilized by G-CSF1AMD3100
were more potent, LTC-IC being 1.4 fold with a range from 1.1X
to 2.6X as compared to that after G-CSF alone. Thus a precise un-
derstanding of the mechanisms behind homing and adhesion of
HPC to the cellular niche has led to the development of a novel
agent for the efficient mobilization of more potent HPC.255
RESCUEMOBILIZATION OF HEMATOPOIETIC PROGENITOR CELLSWITH
AMD3100 1 G-CSF IS SUCCESSFUL IN PATIENTS WHO PREVIOUSLY
FAILED MOBILIZATION
Micallef, I.N.M.1, Ansell, S.M.1, Buadi, F.1, Dispenzieri, A.1,
Elliott, M.A.1, Gertz, M.A.1, Hayman, S.R.1, Hogan, W.J.1,
Inwards, D.J.1, Gastineau, D.A.1, Johnston, P.B.1, Kumar, S.1,
Lacy, M.Q.1, Porrata, L.F.1, Marzolf, M.1, Shaw, T.1, Winters, J.L.2,
Calandra, G.3, Litzow, M.R.1. 1 Mayo Clinic, Rochester, MN; 2 Mayo
Clinic, Rochester, MN; 3 Genzyme Transplant, Cambridge, MA.
Background: The failure rate for hematopoietic progenitor cell
mobilization varies from 5% inMultipleMyeloma pts to 30% in pts
with non-Hodgkin lymphoma and Hodgkin lymphoma.Methods:
We report the results of a single center experience with AMD3100
(plerixafor)1G-CSF as a rescue progenitor cell mobilization in pa-
tients who had failed a prior mobilization. Mobilization failure was
defined as inability to collect$ 2 106 CD341 cells/kg or inability
to achieve a peripheral bloodCD341 cells/ml of$10 and not apher-
esed. Rescue mobilization consisted of G-CSF at 10 mcg/kg/day sq
on days 1–4 plus AMD3100 at 240 mcg/kg/day sq on the evening of
day 4 and continued until the goal of 5  106 CD341 cells/kg was
reached or a maximum of 7 aphereses. Apheresis began on day 5 re-
gardless of the peripheral bloodCD341 cells/ml.Results:Twenty-
nine pts participated in this compassionate use protocol. Demo-
graphics were 11 females and 18 males; 14 pts had NHL, 10 MM,
3 AL amyloidosis and 2 HD. The median age was 63 years (range
37–73). Prior mobilization was G-CSF alone in 25 pts, G-CSF 1
GM-CSF in 2 and chemotherapy 1 G-CSF in 2. Median time
from prior mobilization failure to AMD3100 rescue mobilization
was 0.7 months (range 0.4–33). The median peripheral blood
CD341 cells/ml value prior to AMD3100 was 4.8 (range 0–18.2)
and 12 hours post AMD3100 was 12.4 (range 2–49.5), a 2.7 fold in-
crease (range 0.5–7.4). The median number of CD341 cells har-
vested was 4.71  106 CD341 cells/kg (range 0.25–9.37). Seven
pts (24%) failed to achieve a minimum of $2  106 CD341
cells/kg. Twenty-two of 29 pts (76%) successfully collected at least
2 106 CD341 cells/kg and 12 (41%) collected$ 5 106 CD341
cells/kg. Median number of aphereses in the successful pts was 5
(range 2–7) and the median number of aphereses to reach 2  106
CD341 cells/kg was 2 (range 1–7). Twenty-five pts (86%) went
on to ASCT. This included 4 pts who collected # 2  106
CD341 cells/kg (1.01, 1.44, 1.5, and 1.98) and underwent bone
marrow harvest. One pt who successfully collected has not yet un-
dergone ASCT. All pts had successful engraftment; median time
to neutrophil engraftment (500/ml) was 13 days (range 11–18) and
median time to platelet engraftment (50,000/ml) was 22 days (range
16–231).Conclusion: The addition of AMD3100 to G-CSF effec-
tively mobilizes CD341 cells in themajority of pts, in whom a prior
mobilization with either growth factors or chemotherapy has failed
to mobilize sufficient cells for ASCT.256
POTENTIAL BIODOSIMETRY MARKERS OF RADIATION EXPOSURE
Upton, A., Kharbanda, S., Sande, J.E., Gage, J., Wang, D., Johnson, M.
University of Alabama, Birmingham, AL.
Background: According to a Joint Interagency Group directed
by the Department of Defense, radiological dose assessment is im-
perative to decrease morbidity and mortality following a radiologi-
cal event. Dose assessment requires the development of rapid,
Poster Session I 95minimally invasive assays to be used following mass radiation expo-
sure from biological information stored in the human body. Study
Aim: The goals of this study were to: 1.) identify potential bio-
dosimetry genes from cancer patients following total body irradia-
tion (TBI); 2.) use gene expression analysis in an in vitro system to
develop mathematical models capable of determining radiation
dose received by exposed individuals. Methods/Results: Blood
samples were collected at 5 and 23 hours post-TBI from three pa-
tients with acute lymphocytic leukemia treated over three days
with 2 daily 2 Gy fractions (12 Gy total). Low density array analysis
revealed 15 genes with increased expression post-irradiation. In vi-
tro studies utilized immortalized B lymphocytes irradiated at 0.1,
0.5, 1, and 2 Gy and harvested 3, 5, 9, 12, and 23 hours post-irradi-
ation. Of the 15 genes identified in patients, 10 demonstrated sim-
ilar expression profiles in B lymphocytes. Leukemia Inhibitory
Factor (LIF) and Serine Protease Inhibitor E1 (SERPINE1) dis-
played linear dose-dependent increases in expression at every
time-point as determined by linear regression analyses (r2-val-
ues$0.76, p\ 0.0001). LIF and SERPINE1 followed a time-de-
pendent cubic model of expression to be validated in expanded
time-point studies. Conclusion: The determination of LIF and
SERPINE1 expression may be useful in determining dose of radia-
tion exposure and may subsequently facilitate stratification of indi-
viduals requiring medical intervention.SUPPORTIVE CARE257
DECREASE OF HHV6 DNAemia FOLLOWING ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH CHROMOSO-
MALLY INTEGRATED HHV6
Hubacek, P.1, Hrdlickova, A.2, Muzikova, K.1, Hyncicova, K.2,
Pohlreich, D.3, Cetkovsky, P.3, Sedlacek, P.1. 1 Teaching Hospital Motol,
2nd Medical School, Charles University, Prague, Czech Republic; 2 Teach-
ing Hospital Motol, 2nd Medical School, Charles University, Prague,
Czech Republic; 3 Institute of Hematology and Blood Transfusion, Prague,
Czech Republic.
Immunocompromised patients could suffer from clinical conse-
quences of infection with the human herpesvirus 6 (HHV6). Using
PCRmethods, we are now able to detect viremia while serology re-
sults might be inconclusive in this cohort of patients. Phenomenon
of chromosomal integration of HHV6 (CI-HHV6) however
opened new era in interpretation of HHV6 PCR positivity. Since
CI-HHV6 could be inherited from parent, viral DNA can be de-
tected in every body cell. CI-HHV6 does not represent active
HHV6 infection and its prevalence in population is described be-
tween 1–2%. In such situation, misinterpretation of PCR positivity
may than lead to inadequate and potentially harmful therapy due to
risks of unsubstantiated toxicity and side effects.
In situation of allogeneic HSCT, it is possible to observe increase
in HHV6 positivity caused by the engraftment of the cells from CI-
HHV6 positive donor, or decrease in detected HHV6 DNA after
HSCT in CI-HHV6 positive recipient transplanted with the donor
without CI-HHV6.
Between I/2002-X/2007 we have tested for HHV6 2057 samples
from 219 adult patients and 2553 samples from 107 children
patients after allogeneic HSCT. DNA was isolated from whole
blood and detection was performed using RQ-PCR. Results
were normalised to 10,000 human genomic equivalents accessed
by quantification of albumin gene. HHV6 was detected in 395
samples from 58 children and 144 samples from 40 adults. Within
three weeks after HSCT, we have detected more then 1,000 nor-
malised viral copies in 7 children and 4 adults. From these, we have
confirmed CI-HHV6 by documenting positivity in the pre-trans-
plant samples and the non-blood samples (hair follicles) in one
child and one adult. CI-HHV6 is highly probable also in two pa-
tients with variant B due to long lasting PCR positivity in post-
transplant surveillance and decrease shortly after HSCT (we are
working on CI-HHV6 confirmation). In none of the patients we
have observed post-transplant complications attributable to
HHV6. We excluded CI-HHV6 by the pre-transplant negativity
in the 7 remaining patients.Despite HHV6 is close related to human cytomegalovirus, in this
particular situation patients are endangered only by misinterpreta-
tion of highly positive viral DNA load and side effects of virostatics.
Therefore in case of high HHV6 DNA load we should be aware of
this phenomenon and we should try to excludeCI-HHV6 as soon as
possible.
Supported by FNM 00064203, MSMT0021620813.258
VORICONAZOLE IS EFFECTIVE PROPHYLAXIS FOR ASPERGILLUS INVA-
SIVE FUNGAL INFECTION (IFI) IN PATIENTS RECEIVING GLUCOCORTI-
COSTEROID THERAPY FOR GVHD AFTER ALLOGENEIC
TRANSPLANTATION
Gergis, U.1, Markey, K.2, Greene, J.1, Kharfan-Dabaja, M.1,
Wetzstein, G.2, Anasetti, C.1, Perkins, J.1. 1 H. Lee Moffitt Cancer Cen-
ter & Research Institute, Tampa, FL; 2 H. Lee Moffitt Cancer Center &
Research Institute, Tampa, FL.
Invasive fungal infections (IFI) are a significant cause of morbid-
ity and mortality after allogeneic hematopoietic cell transplant. Pa-
tients (pts) who develop graft versus host disease (GVHD) requiring
systemic glucocorticoids (GC) are especially vulnerable to IFI. The
findings of Ullmann et al. support the prophylactic use of posacona-
zole over either fluconazole (F) or itraconazole (I) in this pt popula-
tion. Efficacy of posaconazole, however, can be limited in pts with
gastrointestinal GVHDby the lack of an IV formulation. Voricona-
zole (V) offers advantages over posaconazole in the availability of an
IV formulation and improved oral bioavailability. Following FDA
approval, we began using V for prophylaxis in patients with
GVHD at the onset of GC therapy. Prior to that time either F or
I was given. To determine the antifungal efficacy of V compared
to F or I, we performed a retrospective review of 169 allogeneic
transplant pts who were placed on GC ($1 mg/kg/d of prednisone
or equivalent) for GVHD. Pts with IFI history before GVHDonset
were excluded. Study endpoints included proportion of pts with
proven or probable IFI by EORTC/MSG criteria during the first
100 days of GC therapy, time to IFI, and mortality due to IFI diag-
nosed within 100 days of the start of GC. Seventy-two pts received
either F (36 pts) or I (36 pts) (F/I) and 97 pts received V. V pts were
older, had higher risk disease, were more likely to have received
transplants of peripheral blood hematopoietic cells and from unre-
lated donors (all risk factors for GVHD and secondary IFI), but
were treated more recently and with reduced intensity regimens.
IFI developed in 7 F/I pts (9.7%) vs 2 V pts (2.1%) (p 5 0.03). F/
I pts included 5 cases (6.9%) of aspergillus (pneumonia [4] and
skin abcess [1]), and 2 cases of candidemia [C. krusei and C. glab-
rata]. V pts included 2 cases of candidemia (C. glabrata) and no as-
pergillus IFI. The proportion of pts developing aspergillus IFI was
significantly lower in the V pts (p 5 0.009). Five of the seven F/I
cases died from the IFI, one of pulmonary hemorrhage and one of
bacterial sepsis. Neither of the 2 V pts died as a result of their
IFI, one died from CNS hemorrhage and the other from GVHD.
Overall survival at 100 days after start of GC was 79% for F/I pts
and 85% for V pts (p 5 0.27). We conclude that voriconazole was
effective prophylaxis for aspergillus IFI in pts receiving GC therapy
for GVHD after allogeneic transplantation.259
TREATMENT OF DONOR GRAFT FAILURE WITH AUTOLOGOUS OR ALLO-
GENEIC STEM CELL BOOST OR A SECOND ALLOGENEIC TRANSPLANT
BASED ON CHIMERISM TESTING
Shimoni, A., Shem-Tov, N., Rand, A., Ribakovsky, E., Yerushalmi, R.,
Hardan, I., Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer,
Israel.
Donor graft failure (GF) is a life-threatening complication of al-
logeneic stem cell transplantation (SCT). We performed this anal-
ysis to determine the rate and outcome of GF in the era of modern
SCT. We retrospectively reviewed data of 491 SCTs from HLA-
matched siblings (n 5 284), matched-unrelated (MUD, n 5 180)
